Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 172

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 172
---
     (12,708,879)
  
    Shares issued as consideration in the Merger 
     -  
     -  
     4,038  
     1  
     47,238,749  
     -  
     -  
     47,238,750 
  
    Loss on VIE consolidation 
     -  
     -  
     -  
     -  
     -  
     -  
     (4,836,216) 
     (4,836,216)
  
    Expense IPR&D 
     -  
     -  
     -  
     -  
     -  
     -  
     (45,640,000) 
     (45,640,000)
  
    Reclassification of public shares 
     -  
     -  
     41  
     -  
     911,358  
     -  
     -  
     911,358 
  
    Issuance of common stock as payment to vendors 
     -  
     -  
     825  
     -  
     3,182,550  
     -  
     -  
     3,182,550 
  
    Elimination of deferred underwriting fees 
     -  
     -  
     -  
     -  
     5,690,000  
     -  
     -  
     5,690,000 
  
    Reclassification of earnout liability 
     -  
     -  
     -  
     -  
     (4,900,000) 
     -  
     -  
     (4,900,000)
  
    Conversion of CERo bridge notes and accrued interest into Series A preferred stock 
     630  
     627,154  
     -  
     -  
     -  
     -  
     -  
     627,154 
  
    Conversion of working capital loan into Series A preferred stock 
     1,605  
     1,555,000  
     -  
     -